Literature DB >> 8335896

Induction of transforming growth factor-beta during cardiac allograft rejection.

J Waltenberger1, A Wanders, B Fellström, K Miyazono, C H Heldin, K Funa.   

Abstract

The polypeptides of the transforming growth factor-beta (TGF-beta) family are potent endogenous immuno-regulators. Using a rat cardiac allograft transplant model, we investigated the expression of the precursor forms of TGF-beta 1, TGF-beta 2, and TGF-beta 3 and the latent TGF-beta binding protein (LTBP) by immunohistochemistry. The activity of TGF-beta in the extracts from transplanted as well as normal hearts was measured using a bioassay, and Northern blot analysis was performed on RNA extracts. The transplanted hearts were analyzed both during acute rejection up to 6 days and during chronic rejection up to 6 mo after transplantation and compared with normal controls. The animals of the chronic rejection group received cyclosporin A for immunosuppression. The TGF-beta bioactivity dramatically increased in the transplanted allografts during the chronic rejection process compared to the normal hearts, and so did the immunostaining as well as the mRNA levels for TGF-beta 1 and, to a lesser extent, the immunostaining for TGF-beta 2. TGF-beta 3 expression remained unchanged and was only found in the myocardium in trace amounts. During the acute rejection process up to 6 days after transplantation, TGF-beta immunoreactivity increased only slightly, whereas the TGF-beta mRNA was severalfold increased. Control animals treated with cyclosporin A showed a similar pattern at day 6 with regard to TGF-beta expression. LTBP was induced simultaneously with TGF-beta 1 and occurred within interstitial spaces of the myocardium. The TGF-beta was produced by macrophage-like infiltrating lymphocytes. In conclusion, highly elevated levels of TGF-beta and LTBP were found during chronic rejection of cardiac allografts in rats. The induction of TGF-beta may counteract the rejection process and could be useful for new therapeutic approaches in the prevention of allograft rejection.

Entities:  

Mesh:

Substances:

Year:  1993        PMID: 8335896

Source DB:  PubMed          Journal:  J Immunol        ISSN: 0022-1767            Impact factor:   5.422


  11 in total

Review 1.  Chronic rejection. A general overview of histopathology and pathophysiology with emphasis on liver, heart and intestinal allografts.

Authors:  A J Demetris; N Murase; R G Lee; P Randhawa; A Zeevi; S Pham; R Duquesnoy; J J Fung; T E Starzl
Journal:  Ann Transplant       Date:  1997       Impact factor: 1.530

2.  Immunocytes of composite tissue allografts express elevated levels of TGF beta mRNA and protein during chronic rejection.

Authors:  K J Walgenbach; R Llull; N Murase; T E Starzl; A Hirner
Journal:  Transplant Proc       Date:  1997 Feb-Mar       Impact factor: 1.066

3.  EGF and TGF-beta1 gene expression in chronically rejecting small bowel transplants.

Authors:  E A Kouwenhoven; A N Stein-Oakley; P Jablonski; R W de Bruin; N M Thomson
Journal:  Dig Dis Sci       Date:  1999-06       Impact factor: 3.199

4.  Cold ischemia induces isograft arteriopathy, but does not augment allograft arteriopathy in non-immunosuppressed hosts.

Authors:  Yutaka Furukawa; Peter Libby; Jennifer L Stinn; Gerold Becker; Richard N Mitchell
Journal:  Am J Pathol       Date:  2002-03       Impact factor: 4.307

Review 5.  The role of antibodies in transplantation.

Authors:  Alexander T Chang; Jeffrey L Platt
Journal:  Transplant Rev (Orlando)       Date:  2009-07-22       Impact factor: 3.943

6.  A critical role for transforming growth factor-beta in donor transfusion-induced allograft tolerance.

Authors:  R Josien; P Douillard; C Guillot; M Müschen; I Anegon; J Chetritt; S Menoret; C Vignes; J P Soulillou; M C Cuturi
Journal:  J Clin Invest       Date:  1998-12-01       Impact factor: 14.808

7.  Liver portal fibrosis in dioxin receptor-null mice that overexpress the latent transforming growth factor-beta-binding protein-1.

Authors:  Javier Corchero; Gervasio Martín-Partido; Sarah L Dallas; Pedro M Fernández-Salguero
Journal:  Int J Exp Pathol       Date:  2004-10       Impact factor: 1.925

8.  Gene transfer for transplantation. Prolongation of allograft survival with transforming growth factor-beta 1.

Authors:  L Qin; K D Chavin; Y Ding; J E Woodward; J P Favaro; J Lin; J S Bromberg
Journal:  Ann Surg       Date:  1994-10       Impact factor: 12.969

9.  Modification of alternative messenger RNA splicing of fibroblast growth factor receptors in human cardiac allografts during rejection.

Authors:  X M Zhao; W H Frist; T K Yeoh; G G Miller
Journal:  J Clin Invest       Date:  1994-09       Impact factor: 14.808

10.  Bone morphogenetic protein type IB receptor is progressively expressed in malignant glioma tumours.

Authors:  N Yamada; M Kato; P ten Dijke; H Yamashita; T K Sampath; C H Heldin; K Miyazono; K Funa
Journal:  Br J Cancer       Date:  1996-03       Impact factor: 7.640

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.